Trading will begin on Friday, October 30, 2009
ALAMEDA, Calif.--(Business Wire)--
BioTime, Inc. (OTCBB: BTIM), a biotechnology company that develops and markets
products in the field of stem cells and regenerative medicine, today announced
that its common stock and warrants have been approved for listing on the NYSE
Amex. Trading is expected to commence on the NYSE Amex on Friday, October 30,
2009 under the same ticker symbols `BTIM` (NYSE Amex: BTIM) for the common stock
and "BTIMW" for the warrants. Prior to that date, BioTime's shares and warrants
will continue to trade on the Over-The-Counter (OTC) Bulletin Board.
"We are pleased to be moving our stock listing from the OTC Bulletin Board to
the NYSE Amex," said Michael D. West, Ph.D., President and Chief Executive
Officer of BioTime, Inc. "This listing marks an important strategic advancement
for the Company in regard to raising our profile in the stem cell sector and
improving our stock`s liquidity. It will also improve our visibility as we
continue to make progress on our corporate objectives."
"We welcome BioTime, Inc. to the NYSE Euronext family of listed companies and to
NYSE Amex," said Scott Culter, NYSE Euronext Executive Vice President and Head
of Listings, Americas. "BioTime and the company`s shareholders will benefit from
superior market quality and technology, a broad array of issuer and investor
services, and global brand association. We look forward to building a strong and
lasting partnership with the BioTime team and their shareholders."
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. BioTime
develops and markets research products in the field of stem cells and
regenerative medicine through its wholly owned subsidiary Embryome Sciences,
Inc. BioTime`s subsidiary OncoCyte Corporation focuses on the therapeutic
applications of stem cell technology in cancer. BioTime also plans to develop
therapeutic products in China for the treatment of ophthalmologic, skin,
musculo-skeletal system and hematologic diseases, including the targeting of
genetically modified stem cells to tumors as a novel means of treating currently
incurable forms of cancer through its subsidiary BioTime Asia. In addition to
its stem cell products, BioTime markets blood plasma volume expanders and
related technology for use in surgery, emergency trauma treatment, and other
applications. BioTime's lead product, Hextend®, is a blood plasma volume
expander manufactured and distributed in the U.S. by Hospira, Inc. and in South
Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional
information about BioTime can be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development and potential opportunities
for the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,") should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0
BioTime, Inc.
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com
Copyright Business Wire 2009
